Genetic modification of cardiac fibroblasts in adult rats using adeno-associated virus serotype 9

Abstract

Cardiac fibrosis is a process involving pathological extracellular matrix remodeling as well as cardiac fibroblast (CF) activation in response to cardiac injury and stress, which is frequently associated with cardiac dysfunction. Therefore, understanding the molecular mechanisms underlying CF activation is critical to develop successful therapies for treating cardiac fibrosis. CF-specific gene modifications in mouse models have been reported as key tools for cardiac fibrosis research. Although rat cardiac disease models also offer many of the same advantages as the mouse models, there are no rat models that employ CF-specific conditional gene modification. Here, we attempted CF-specific gene introduction in rats using adeno-associated virus serotype 9 (AAV9), allowing us to develop fast and simple rat cardiac disease models rather than establishing transgenic rat lines. AAV9 carrying a CF-specific human TCF21 (hTCF21) promoter and a transgene of interest was generated and introduced into adult rats via tail vein injections. Since we previously reported in cultured CFs that protein kinase D (PKD) activation at the outer mitochondrial membrane (OMM) induces mitochondrial fragmentation via phosphorylation of a mitochondrial fission protein DRP1, we generated an OMM-targeted dominant-negative mutant of PKD (termed mt-PKD-DN) to specifically inhibit PKD activity at the OMM in CFs in vivo. In vivo cardiac function, gene expression, protein expression, and mitochondrial morphology were assessed 2-10 weeks after AAV9 injection by echocardiography, quantitative RT-PCR, immunohistochemistry, and transmission electron microscopy (TEM), respectively. AAV9-hTCF21-injected rats maintained normal cardiac dimensions and contractile function compared to aged-matched control rats. Using AAV9-hTCF21-EGFP, we confirmed organ-specific (i.e., heart) and cell type-specific (i.e., CF-specific) expression of GFP. Next, we injected AAV9-hTCF21-mt-PKD-DN or -luciferase (Luc) as a control in adult rats. TEM images from fixed rat ventricular tissues revealed a significant increase in mitochondrial aspect ratio and mitochondrial perimeter in CFs with AAV9-hTCF21-mt-PKD-DN compared to AAV9-hTCF21-Luc, indicating that PKD inhibition at the OMM induces mitochondrial elongation in CFs in vivo. In contrast, no significant change in mitochondrial morphology was observed in the cardiomyocyte area. In summary, we successfully achieved a CF-specific gene delivery to the adult rat hearts in vivo, demonstrating the potential of a simplified CF-specific rat transgenic model using the AAV9-hTCF21 system. NIH/NHLBI R01HL160699. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.